Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 25 15 versus PERINDOPRIL ERBUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 25 15 versus PERINDOPRIL ERBUMINE.
CAPOZIDE 25/15 vs PERINDOPRIL ERBUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of captopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Perindopril is a prodrug that is hydrolyzed to perindoprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and catecholamine release, leading to decreased blood pressure.
Oral: 1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) once daily initially; titrate to a maximum of 2 tablets twice daily based on blood pressure response.
2.5–10 mg orally once daily; initial dose 2.5 mg for hypertension, 4 mg for stable coronary artery disease; titrate based on response.
None Documented
None Documented
Captopril: ~2 hours (terminal) in normal renal function; increases to 20-60 hours in severe renal impairment. Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
The terminal elimination half-life of perindopril is 1.5–3 hours, but for the active metabolite perindoprilat it is 30–120 hours, due to slow dissociation from tissue ACE. This long half-life supports once-daily dosing for 24-hour blood pressure control.
Captopril: 95% renally excreted, primarily as unchanged drug and metabolites (disulfide dimers). Hydrochlorothiazide: at least 95% renally excreted as unchanged drug.
Perindopril is extensively metabolized to perindoprilat. Approximately 75% of an oral dose is excreted in urine (as perindoprilat and metabolites) and 25% in feces (mainly as perindoprilat). Less than 5% is excreted unchanged in urine. Biliary excretion is minimal.
Category C
Category D/X
ACE Inhibitor and Diuretic Combination
ACE Inhibitor